Annual EBIT
-$36.38 M
+$1.17 M+3.12%
31 December 2023
Summary:
Kala Pharmaceuticals annual earnings before interest & taxes is currently -$36.38 million, with the most recent change of +$1.17 million (+3.12%) on 31 December 2023. During the last 3 years, it has risen by +$59.35 million (+62.00%). KALA annual EBIT is now -126.30% below its all-time high of -$15.75 million.KALA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$7.47 M
+$649.00 K+7.99%
30 September 2024
Summary:
Kala Pharmaceuticals quarterly earnings before interest & taxes is currently -$7.47 million, with the most recent change of +$649.00 thousand (+7.99%) on 30 September 2024. Over the past year, it has dropped by -$227.00 thousand (-3.13%). KALA quarterly EBIT is now -124.48% below its all-time high of $30.52 million, reached on 30 September 2022.KALA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$33.10 M
-$227.00 K-0.69%
30 September 2024
Summary:
Kala Pharmaceuticals TTM earnings before interest & taxes is currently -$33.10 million, with the most recent change of -$227.00 thousand (-0.69%) on 30 September 2024. Over the past year, it has increased by +$7.39 million (+18.25%). KALA TTM EBIT is now -1113.93% below its all-time high of -$2.73 million, reached on 30 June 2023.KALA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALA EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.1% | -3.1% | +18.3% |
| 3 y3 years | +62.0% | +71.3% | +71.9% |
| 5 y5 years | +42.6% | +64.4% | +62.9% |
KALA EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +72.9% | -124.5% | +83.6% | -1113.9% | +75.8% |
| 5 y | 5 years | at high | +72.9% | -124.5% | +83.6% | -1113.9% | +75.8% |
| alltime | all time | -126.3% | +72.9% | -124.5% | +83.6% | -1113.9% | +75.8% |
Kala Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$7.47 M(-8.0%) | -$33.10 M(+0.7%) |
| June 2024 | - | -$8.12 M(-21.6%) | -$32.88 M(-2.6%) |
| Mar 2024 | - | -$10.35 M(+44.6%) | -$33.76 M(-7.2%) |
| Dec 2023 | -$36.38 M(-3.1%) | -$7.16 M(-1.2%) | -$36.38 M(-10.1%) |
| Sept 2023 | - | -$7.25 M(-19.5%) | -$40.49 M(+1384.9%) |
| June 2023 | - | -$9.00 M(-30.7%) | -$2.73 M(-86.1%) |
| Mar 2023 | - | -$12.98 M(+15.2%) | -$19.63 M(-47.7%) |
| Dec 2022 | -$37.56 M(-72.0%) | -$11.27 M(-136.9%) | -$37.56 M(-47.7%) |
| Sept 2022 | - | $30.52 M(-217.8%) | -$71.78 M(-44.1%) |
| June 2022 | - | -$25.90 M(-16.2%) | -$128.36 M(-6.2%) |
| Mar 2022 | - | -$30.91 M(-32.1%) | -$136.86 M(+2.0%) |
| Dec 2021 | -$134.22 M(+40.2%) | -$45.49 M(+74.6%) | -$134.22 M(+14.1%) |
| Sept 2021 | - | -$26.05 M(-24.3%) | -$117.67 M(+0.2%) |
| June 2021 | - | -$34.41 M(+21.7%) | -$117.41 M(+12.7%) |
| Mar 2021 | - | -$28.27 M(-2.3%) | -$104.18 M(+8.8%) |
| Dec 2020 | -$95.74 M | -$28.94 M(+12.2%) | -$95.74 M(+10.5%) |
| Sept 2020 | - | -$25.79 M(+21.8%) | -$86.61 M(+5.9%) |
| June 2020 | - | -$21.18 M(+6.8%) | -$81.81 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$19.83 M(+0.1%) | -$82.40 M(-4.0%) |
| Dec 2019 | -$85.87 M(+35.4%) | -$19.81 M(-5.6%) | -$85.87 M(-3.7%) |
| Sept 2019 | - | -$21.00 M(-3.5%) | -$89.17 M(+7.0%) |
| June 2019 | - | -$21.76 M(-6.6%) | -$83.35 M(+10.0%) |
| Mar 2019 | - | -$23.29 M(+0.8%) | -$75.79 M(+19.5%) |
| Dec 2018 | -$63.42 M(+54.0%) | -$23.12 M(+52.4%) | -$63.43 M(+23.9%) |
| Sept 2018 | - | -$15.17 M(+6.8%) | -$51.20 M(+11.3%) |
| June 2018 | - | -$14.21 M(+30.0%) | -$45.99 M(+8.1%) |
| Mar 2018 | - | -$10.93 M(+0.4%) | -$42.56 M(+3.3%) |
| Dec 2017 | -$41.19 M(+27.1%) | -$10.89 M(+9.3%) | -$41.19 M(+7.0%) |
| Sept 2017 | - | -$9.96 M(-7.6%) | -$38.50 M(+1.3%) |
| June 2017 | - | -$10.78 M(+12.7%) | -$38.01 M(+3.0%) |
| Mar 2017 | - | -$9.56 M(+16.7%) | -$36.90 M(+13.9%) |
| Dec 2016 | -$32.40 M(+101.5%) | -$8.19 M(-13.6%) | -$32.40 M(+33.9%) |
| Sept 2016 | - | -$9.48 M(-1.9%) | -$24.21 M(+64.4%) |
| June 2016 | - | -$9.67 M(+91.1%) | -$14.72 M(+191.1%) |
| Mar 2016 | - | -$5.06 M | -$5.06 M |
| Dec 2015 | -$16.08 M | - | - |
FAQ
- What is Kala Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals annual EBIT year-on-year change?
- What is Kala Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals quarterly EBIT year-on-year change?
- What is Kala Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals TTM EBIT year-on-year change?
What is Kala Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of KALA is -$36.38 M
What is the all time high annual EBIT for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high annual earnings before interest & taxes is -$15.75 M
What is Kala Pharmaceuticals annual EBIT year-on-year change?
Over the past year, KALA annual earnings before interest & taxes has changed by +$1.17 M (+3.12%)
What is Kala Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of KALA is -$7.47 M
What is the all time high quarterly EBIT for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high quarterly earnings before interest & taxes is $30.52 M
What is Kala Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, KALA quarterly earnings before interest & taxes has changed by -$227.00 K (-3.13%)
What is Kala Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of KALA is -$33.10 M
What is the all time high TTM EBIT for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high TTM earnings before interest & taxes is -$2.73 M
What is Kala Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, KALA TTM earnings before interest & taxes has changed by +$7.39 M (+18.25%)